Department of Infectious Diseases, Molecular Virology, Otto Meyerhof Zentrum, University of Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany.
J Virol. 2010 Feb;84(4):1989-2000. doi: 10.1128/JVI.01902-09. Epub 2009 Dec 9.
Previous studies showed that the N-terminal 75 amino acids of the pre-S1 domain of the hepatitis B virus (HBV) L protein are essential for HBV and hepatitis delta virus (HDV) infectivity. Consistently, synthetic lipopeptides encompassing this sequence or only parts of it efficiently block HBV and HDV infection, presumably through specific interference with a cellular receptor. Crucial for both virus infectivity and the inhibitory activity of the peptides are N-terminal myristoylation and a highly conserved motif within the N-terminal 48 amino acids. To refine the sequence requirements, we synthesized a series of HBV pre-S1 peptides containing deletions, point mutations, d-amino acid exchanges, or genotype-specific sequence permutations. Using the HepaRG cell line and a genotype D-derived virus, we determined the specific inhibitory activities of the peptides and found that (i) lipopeptides with an artificial consensus sequence inhibit HBV genotype D infection more potently than the corresponding genotype D peptides; (ii) point mutations, d-amino acid exchanges, or deletions introduced into the highly conserved part of the pre-S1 domain result in an almost complete loss of activity; and (iii) the flanking sequences comprising amino acids 2 to 8, 16 to 20, and, to a less pronounced extent, 34 to 48 gradually increase the inhibitory activity, while amino acids 21 to 33 behave indifferently. Taken together, our data suggest that HBV pre-S1-mediated receptor interference and, thus, HBV receptor recognition form a highly specific process. It requires an N-terminal acyl moiety and a highly conserved sequence that is present in primate but not rodent or avian hepadnaviruses, indicating different entry pathways for the different family members.
先前的研究表明,乙型肝炎病毒 (HBV) L 蛋白前 S1 结构域的 N 端 75 个氨基酸对于 HBV 和乙型肝炎 delta 病毒 (HDV) 的感染是必需的。一致地,包含该序列或仅其部分的合成脂肽有效地阻止了 HBV 和 HDV 的感染,推测是通过与细胞受体的特异性干扰。对于病毒感染性和肽的抑制活性都至关重要的是 N 端豆蔻酰化和 N 端 48 个氨基酸内的高度保守基序。为了细化序列要求,我们合成了一系列包含缺失、点突变、D-氨基酸交换或基因型特异性序列置换的 HBV 前 S1 肽。使用 HepaRG 细胞系和基因型 D 衍生的病毒,我们确定了肽的特定抑制活性,并发现:(i) 具有人工共识序列的脂肽比相应的基因型 D 肽更有效地抑制 HBV 基因型 D 感染;(ii) 引入前 S1 结构域高度保守部分的点突变、D-氨基酸交换或缺失导致几乎完全丧失活性;和 (iii) 包含氨基酸 2 至 8、16 至 20 的侧翼序列,并且在较小程度上包含 34 至 48 的侧翼序列逐渐增加抑制活性,而氨基酸 21 至 33 的行为则无差异。总之,我们的数据表明,HBV 前 S1 介导的受体干扰,因此,HBV 受体识别形成了一个高度特异性的过程。它需要一个 N 端酰基部分和一个高度保守的序列,该序列存在于灵长类动物中,但不存在于啮齿动物或禽类嗜肝病毒中,表明不同的家族成员有不同的进入途径。